Drug Approval | March 17, 2022
Lynparza reduced risk of death by 32% in the adjuvant treatment of patients with breast cancer
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
This pre-packaged release is a ready-to-go solution with powerful, straightforward bioanalysis pipeline support
The meeting was co-organized by World Health Organization’s Country Office for India, World Animal Protection India and ReAct Asia Pacific
The centre will initially employ 170 engineers, bringing the total number of Boston Scientific’s R&D employees in India to more than 300
This investment will help BSV avoid carbon dioxide emissions by as much as 6560 tonnes of carbon dioxide equivalent (tCO2e) annually over its project life of 25 years
Tapestri Platform powers Nature Cardiovascular Research publication that identifies two somatic mutations associated with sporadic brain blood vessel disorder
The TAT-5000 and the TAT-2000 thermometers for professional use by doctors and nurses and the TAT-2000C thermometer for consumer applications are based on a very innovative infrared technology
The SMILE-100 System is a breast thermography device that helps healthcare personnel review, measure and analyze thermally significant indications in the breast region
Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection
Ritonavir oral tablet is a pharmacokinetic booster of multiple oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid (Nirmatrelvir 300 mg tablet + ritonavir 100 mg tablet co-administration package)
Subscribe To Our Newsletter & Stay Updated
